Langerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity  by Fujita, Hideki et al.
Langerhans Cells from Human Cutaneous Squamous
Cell Carcinoma Induce Strong Type 1 Immunity
Hideki Fujita1, Mayte Sua´rez-Farin˜as1,2, Hiroshi Mitsui1, Juana Gonzalez3, Mark J. Bluth1, Shali Zhang4,
Diane Felsen5, James G. Krueger1 and John A. Carucci4
Langerhans cells (LCs) are dendritic cells (DCs) localized to the epidermis. They should be the first antigen-
presenting cells to encounter squamous cell carcinoma (SCC). The aim of this study was to investigate
the ability of LCs isolated from human SCC to induce T-cell proliferation and polarization. We investi-
gated the ability of LCs from SCC and peritumoral skin to induce T-cell proliferation and polarization.
We also studied the effect of SCC supernatant on the ability of LCs from normal skin, in vitro–generated
LCs, and DCs to activate and polarize T cells. LCs from SCC were stronger inducers of allogeneic CD4þ
and CD8þ T-cell proliferation and IFN-g production than LCs from peritumoral skin. We found that
tumor supernatants (TSNs) were rich in immunosuppressive cytokines; despite this, allogeneic CD4þ
and CD8þ T-cell proliferation and IFN-g induction by LCs were augmented by TSN. Moreover, TSN
facilitated IFN-g induction by in vitro–generated LCs, but suppressed the ability of in vitro–generated DCs
to expand allogeneic CD4þ and CD8þ T cells. We have demonstrated that LCs from SCC can induce
type 1 immunity. TSN induces IFN-g induction by in vitro–generated LCs. This contrasts greatly with prior
studies showing that DCs from SCC cannot stimulate T cells. These data indicate that LCs may be superior
to DCs for SCC immunotherapy and may provide a new rationale for harnessing LCs for the treatment of cancer
patients.
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INTRODUCTION
Dendritic cells (DCs) are the most potent antigen-presenting
cells, comprise a variety of subsets, and serve as master
regulators of adaptive immunity (Fricke and Gabrilovich,
2006; Steinman and Banchereau, 2007). Because of their
potential to elicit tumor-specific T-cell responses, it is
generally accepted that DCs have key roles in cancer
immune surveillance (Gottfried et al., 2008). Numerous
studies have demonstrated that DCs often infiltrate various
human tumors (Vicari et al., 2002; Talmadge et al., 2007;
Chaput et al., 2008). However, DCs from some cancers are
functionally compromised (Pinzon-Charry et al., 2005; Fricke
and Gabrilovich, 2006; Bennaceur et al., 2008; Chaput et al.,
2008; Gottfried et al., 2008). Many studies have demon-
strated decreased ability of DCs from human cancer to
stimulate T cells and induce IFN-g (Enk et al., 1997;
Gabrilovich et al., 1997; Nestle et al., 1997; Troy et al.,
1998; Curiel et al., 2003; Perrot et al., 2007). Hence, it has
been postulated that dysfunction of DCs, induced by the
tumor microenvironment, may allow tumors to escape
immune surveillance (Pinzon-Charry et al., 2005).
The deficit of endogenous DCs frequently observed
in cancer patients led to the use of ex vivo–generated
DCs as carriers of cancer vaccines (Pinzon-Charry et al.,
2005; Kalinski et al., 2009). Clinical trials using ex
vivo–generated DCs have occasionally yielded significant
tumor regression (Steinman and Banchereau, 2007; Kalinski
et al., 2009). However, objective clinical benefits are very
limited, arguing for the need to improve the design of DC-
based vaccines (Rosenberg et al., 2004; Banchereau and
Palucka, 2005). In particular, even the appropriate DC subset
for clinical use remains undefined. Given the functional
differences among DC subsets, further understanding of the
biology of each DC subset in the complex tumor-associated
environment is crucial (Shurin and Lotze, 2009; Ueno et al.,
2010).
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The skin immune system harbors a rich network of DCs,
mainly composed of epidermal Langerhans cells (LCs) and
dermal myeloid DCs. We and others have demonstrated that
dermal myeloid DCs, associated with cutaneous basal cell
carcinoma and squamous cell carcinoma (SCC), are deficient
in their ability to stimulate T cells (Nestle et al., 1997;
Bluth et al., 2009). We have previously shown that the
number of LCs is significantly decreased in SCC, which
corroborates previous observations by others (Galan and Ko,
2007; Takahara et al., 2009). However, the functional
significance of LCs in human cutaneous SCC remains
undefined.
As cutaneous SCC is a malignant proliferation of epidermal
keratinocytes, LCs should be the first antigen-presenting cells
to encounter tumor antigens. This prompted us to study the
functional properties of LCs in cutaneous SCC. Here, we
report observations, which to our knowledge are previously
unreported, relating to the potential value of using LCs for
cancer immunotherapy.
By using human SCC specimens, we show that epidermal
LCs, and in vitro–generated LCs, can be activated to elicit
desirable type 1 immunity. This is in direct contrast to what we
previously found for myeloid DCs in SCC, and thus demon-
strates the unique biology of LCs, which can be exploited for
therapeutic advantage. Our findings provide a new rationale
for harnessing both in vivo– and in vitro–generated LCs for
cancer treatment. Manipulation of LCs generated from human
blood precursors to drive antitumor response may be
particularly useful in adoptive immunotherapy.
RESULTS
LCs from human SCC are more mature compared with LCs from
peritumoral nonlesional skin
As DC maturation is a key event in the induction of the
immune responses, we first characterized the maturation
status of LCs from SCC by analyzing the expression of
maturation makers. HLA-DRþCD207þ cells from epider-
mal cell suspensions derived from SCC and peritumoral
nonlesional (PTNL) skin were defined as LCs and evaluated
for CD40, CD80, CD83, and CD86 expression by flow
cytometry. SCC-derived LCs expressed higher levels of CD40,
CD80, CD83, and CD86 compared with LCs from patient-
matched PTNL skin (Figure 1). HLA-DRþCD207 cells were
observed in 50% of cases. These cells did not express CD40,
CD83, CD86, or common leukocyte antigen CD45, and were
thus likely to be tumor cells.
LCs from human SCC are more powerful stimulators of
allogeneic CD4þ and CD8þ T-cell proliferation than those
from PTNL skin
To explore whether the more mature phenotype of SCC-
derived LCs was linked to their capacity to stimulate T-cell
proliferation, we performed mixed leukocyte reactions
(MLRs). Carboxyfluorescein diacetate succinimidyl ester
(CFSE)-labeled allogeneic total T cells from peripheral blood
were cocultured with FACS-sorted HLA-DRþCD207þ LCs
from either SCC tumor nests or patient-matched PTNL
skin for 7 days; T-cell proliferation was then assessed by
flow cytometry. We set gates on live CD3þCD4þ and
CD3þCD8þ cells for analysis and evaluated T-cell prolifera-
tion by CFSE dilution. As shown in Figure 2a, LCs from SCC
induced significantly higher levels of allogeneic CD4þ and
CD8þ T-cell proliferation than those from PTNL skin.
Representative FACS histograms are shown in Figure 2b.
LCs from human SCC induce type 1 T-cell response more
efficiently than those from PTNL skin
Next, we examined cytokine profiles of T cells activated by
LCs from SCC and those from PTNL skin. We focused on the
cytokines associated with specific T helper (Th) cell subtypes,
including IFN-g (Th1), IL-4 (Th2), IL-17 (Th17), and IL-22
(Th22). Total allogeneic T cells cultured with FACS-sorted
PTNL skin
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Figure 1. Flow cytometric analysis of maturation-associated molecules expressed on Langerhans cells (LCs) from squamous cell carcinoma (SCC) and
peritumoral nonlesional (PTNL) skin. HLA-DRþCD207þ LCs in the epidermal cell suspension from SCC and PTNL skin were subjected to the analysis of cell
surface expression of CD40, CD80, CD83, and CD86. Dashed lines indicate isotype controls. Mean fluorescence intensity value is shown in the upper right-
hand corner of each histogram. Data are representative of three independent experiments.
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Figure 2. Langerhans cells (LCs) from squamous cell carcinoma (SCC) stimulate proliferation of IFN-c-producing CD4þ and CD8þ T cells. (a)
Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled, allogeneic T cells were cultured with FACS-sorted LCs from SCC or peritumoral nonlesional
(PTNL) skin. Percentages of proliferating cells within live CD3þCD4þ and CD3þCD8þ cells were determined by CFSE dilution. (b) Representative FACS
histograms of CFSE dilution assay using LCs from SCC and PTNL skin. Numbers show percentages of proliferating (CFSElow) cells. (c) Frequencies of cells positive
for intracellular IFN-g, IL-4, IL-17, and IL-22 detected in proliferating CD4þ and CD8þ T-cell populations following LC coculture experiments. NS, not
significant. (d) Dot plot analysis of IFN-g, IL-4, IL-17, and IL-22 expression in proliferating CD4þ and CD8þ T cells stimulated by LCs from SCC versus PTNL
skin. Numbers indicate percent gated cells.
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LCs for 7 days were subsequently activated by phorbol 12-
myristate 13-acetate and ionomycin for 4 hours in the
presence of brefeldin A, followed by intracellular cytokine
staining. The percentages of T cells producing IFN-g (Th1), IL-
4 (Th2), IL-17 (Th17), and IL-22 (Th22) are shown in Figure
2c. LCs from SCC induced significantly greater percentages of
IFN-g-producing cells than those from PTNL skin in both
CD4þ and CD8þ T cells. The frequencies of CD4þ and
CD8þ T cells producing IL-4, IL-17, and IL-22 were not
different between the two groups. The percentages of
IFN-producing T cells did not vary with numbers of LCs
isolated per skin sample. Representative FACS plots of
cytokine production by proliferating T cells are shown in
Figure 2d.
LCs from SCC show a mixed gene expression profile with both
immune activation and immune tolerance genes
We were interested in determining the genomic signature
of SCC-associated LCs, as they were unexpectedly more
stimulatory than those from PTNL skin. Gene array analysis
was performed to compare LCs isolated from SCC and those
from patient-matched PTNL skin with verification of FACS
analysis (see Supplementary Results and Supplementary
Figure S1 online). We found that molecules associated with
DC maturation and activation, including signal transducer
and activator of transcription (STAT)-4, IL-15, LY75/CD205,
CD80, IL-2RA/CD25, STAT-5B, and STAT-5A, were upregu-
lated exclusively in SCC-derived LCs (Supplementary
Table S1 online). Interestingly, molecules that can be
involved in immune tolerance, such as CD200 and receptor
activator of NF-kB, were also upregulated in LCs from SCC.
Three probes corresponding to CLEC2D showed increased
expression in SCC-associated LCs (3.498- to 4.768-fold,
Po0.0001 0.00.4, Supplementary Table S2 online).
CLEC2D has been linked to IFN-g via interaction with its
receptor, CD161, which is expressed on T cells (Aldemir
et al., 2005).
SCC supernatant enhances CD4þ and CD8þ T-cell
proliferation induced by LCs
As LCs should present tumor antigens to T cells in the
context of the SCC-associated environment in vivo, we
were also interested in how soluble factors released from
the SCC microenvironment affect the interaction of LCs
and T cells. To simulate the interaction of LCs and T cells
in the SCC microenvironment, SCC culture supernatants
were prepared and added to MLR experiments. FACS-sorted
LCs from normal epidermis and CFSE-labeled allogeneic
total T cells from peripheral blood were cocultured for
7 days in the presence or absence of 25% tumor supernatant
(TSN) from SCC; then, T-cell proliferation was assessed
as described above. Interestingly, as shown in Figure 3a,
TSN applied to MLR assays significantly augmented the
proliferation of both CD4þ and CD8þ T cells triggered
by LCs. When T cells were cultured in the presence of
TSN without LCs, their proliferation was not observed (data
not shown). Representative FACS histograms are shown in
Figure 3b.
SCC supernatant facilitates the generation of a broad range of
CD4þ T cells, as well as IFN-c-producing CD8þ T cells among
T cells expanded by LCs
We also investigated the cytokine profile of T cells stimulated
by LCs in the presence or absence of TSN as described above.
As shown in Figure 3c, the addition of TSN to MLR culture
significantly increased the frequencies of the cells producing
IFN-g, IL-4, IL-17, and IL-22 among proliferating CD4þ T
cells. With respect to CD8þ T cells, only the frequency of the
cells producing IFN-g was increased by TSN. Representative
FACS plots of cytokine production by proliferating T cells are
shown in Figure 3d.
SCC supernatant enhances the proliferation of CD4þ and
CD8þ T cells induced by in vitro–generated LC-type DCs,
whereas it suppresses T-cell proliferation driven by
monocyte-derived DCs
For in vitro–generated DC-based vaccine therapy for cancer
patients, DCs are prepared by the culture of CD34þ
hematopoietic progenitor cells (HPCs) in the presence of
GM-CSF, tumor necrosis factor-a (TNF-a), and fms-like
tyrosine kinase 3 ligand or by culturing blood-derived
monocytes in the presence of GM-CSF and IL-4 (El Marsafy
et al., 2009). It is noteworthy that DCs derived from CD34þ
HPCs contain CD1aþCD14 LC-type DCs. Therefore, we
were further interested in whether CD34þ HPC-derived
LC-type DCs were also capable of stimulating T cells
effectively in the tumor-associated environment. We assessed
the capability of the LC-type DCs to activate allogeneic
T cells in the presence of SCC supernatant as above. We also
used monocyte-derived DCs from the same donors for
comparison. As shown in Supplementary Figure S2 online,
we were able to obtain CD1aþCD14 cells with an LC
phenotype by culturing CD34þ HPCs with GM-CSF, TNF-a,
and fms-like tyrosine kinase 3 ligand. Monocyte-derived
DCs were obtained by culturing monocytes with GM-CSF
and IL-4.
Consistent with our observations from normal epidermal
LCs, the presence of TSN in MLR culture significantly
Figure 3. Tumor supernatant (TSN) enhances Langerhans cell (LC)-driven CD4þ and CD8þ T-cell proliferation, IFN-c, IL-4, IL-17, and IL-22 production by
CD4þ cells, and IFN-c production by CD8þ cells. (a) LCs from normal skin were cultured with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled
allogeneic T cells in the presence or absence of 25% TSN. Percentages of proliferating cells within live CD3þCD4þ and CD3þCD8þ cells were determined by
CSFE dilution. (b) FACS histograms of CFSE dilution assay using LCs and TSN. Numbers show percentages of proliferating cells. (c) The effect of TSN on
production of IFN-g, IL-4, IL-17, and IL-22 by CD4þ and CD8þ T cells. NS, not significant. (d) Dot plot analysis of IFN-g, IL-4, IL-17, and IL-22 expression in
proliferating CD4þ and CD8þ T cells stimulated by LCs in the presence or absence of TSN. Numbers show percent gated cells.
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enhanced the proliferation of both CD4þ and CD8þ T cells
triggered by LC-type DCs (Figure 4a). On the other hand, the
proliferation of both CD4þ and CD8þ T cells induced by
monocyte-derived DCs was significantly suppressed by
adding TSN to culture. Representative FACS histograms are
shown in Figure 4b.
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Figure 4. Tumor supernatant (TSN) enhances proliferation and IFN-c response by CD4þ and CD8þ T cells induced by in vitro–generated Langerhans cells
(LCs), but suppresses those by monocyte-derived dendritic cells (mono-DCs). (a) CD1aþCD14 LC-type DCs derived from CD34þ hematopoietic progenitors,
or mono-DCs, were cultured with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled T cells in the presence or absence of 25% TSN. Percentages of
proliferating cells were determined by CFSE dilution. (b) FACS histograms of CFSE dilution assay. Numbers show percentages of proliferating cells. (c) Effect of
TSN on in vitro–generated LC- or DC-driven production of IFN-g, IL-4, IL-17, or IL-22, by CD4þ and CD8þ T cells. NS, not significant. (d) Dot plot analysis of
IFN-g, IL-4, IL-17, and IL-22 expression in proliferating CD4þ and CD8þ T cells stimulated by LC-type DCs or mono-DCs in the presence or absence of TSN.
Numbers show percent gated cells.
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SCC supernatant enhances type 1 T-cell response elicited by
in vitro–generated LC-type DCs, but suppresses that induced by
monocyte-derived DCs
The cytokine profiles of T cells stimulated by LC-type DCs
and monocyte-derived DCs in the presence or absence of
SCC supernatant were examined as well. As shown in Figure
4c, the percentages of IFN-g-producing cells among prolif-
erating CD4þ and CD8þ T cells stimulated by LC-type DCs
were significantly increased by the presence of TSN in
culture. The addition of TSN also elevated the frequency of
IL-17-producing CD4þ T cells activated by LC-type DCs. In
contrast, the presence of TSN in culture significantly reduced
the percentages of the cells expressing IFN-g among
proliferating CD4þ and CD8þ T cells stimulated by
monocyte-derived DCs. Thus, type 1 immune response
induced by LC-type DCs was promoted by TSN, whereas
that induced by monocyte-derived DCs was attenuated.
Representative FACS plots of cytokine production by
proliferating T cells are shown in Figure 4d. Overall,
monocyte-derived DCs were less able than LCs to stimulate
T cells than LCs with media alone (Supplementary Figure S3
online). In another series of experiments, LCs or DCs,
generated in vitro, were pretreated with TSN and extensively
washed before culturing with allogeneic T cells. TSN
pretreatment enhanced the ability of in vitro–generated LCs
to drive T-cell proliferation, and it suppressed the ability of
in vitro–generated DCs to drive allogeneic T-cell proliferation
(Supplementary Figure S4 online).
SCC supernatants contain cytokines that suppress myeloid DCs
Abundant evidence indicates that immunosuppressive cyto-
kines in the tumor microenvironment impair DC differentia-
tion and function (Zou, 2005; Fricke and Gabrilovich, 2006).
Indeed, in a previous study, we have shown high mRNA
expression of IL-10, vascular endothelial growth factor
(VEGF), and transforming growth factor-b1 (TGF-b1) in
cutaneous SCC specimens (Bluth et al., 2009). To identify
the cytokine milieu of cutaneous SCC in more detail, we
screened TSNs from SCC specimens for the production of
cytokines. The amounts of IFN-g, IL-1b, IL-2, IL-6, IL-8, IL-
12p70, TNF-a, GM-CSF, IL-10, VEGF, and TGF-b1 in TSNs
were measured by an electrochemiluminescence-based
system (n¼12). As shown in Table 1, SCC supernatants
contained significant levels of IFN-g (9.8±2.4 pgml–1; 4 out
of 12 samples), IL-1b (22.5±6.9 pgml–1; 11 out of 12
samples), IL-2 (4.1±0.8 pgml–1; 10 out of 12 samples), IL-6
(450±245pgml–1; 11 out of 12 samples), IL-8 (7585±
1651pgml–1; 12 out of 12 samples), IL-12p70 (1.0±
0.2 pgml–1; 7 out of 12 samples), TNF-a (23.4±6.2 pgml–1;
5 out of 12 samples), GM-CSF (109±49 pgml–1; 9 out of
12 samples), IL-10 (12.2±2.7 pgml–1; 9 out of 12 samples),
and VEGF (408±120 pgml–1; 12 out of 12 samples; mean±
SEM for all). We could not detect these cytokines in
culture media used for culturing tumor samples (n¼ 3).
Of 12 TSN samples, 11 had higher concentrations of
TGF-b1 (33.5±4.4 pgml
–1) than the media used for the
culture (baseline level). Thus, TSNs from cutaneous SCCs
Table 1. Cytokines in the supernatants of whole-SCC tumor specimen culture
Sample
no.
IFN-c
(pgml–1)
IL-1b
(pgml–1)
IL-2
(pgml–1)
IL-6
(pgml–1)
IL-8
(pgml–1)
TNF-a
(pgml–1)
IL-12p70
(pgml–1)
GM-CSF
(pgml–1)
IL-10
(pgml–1)
VEGF
(pgml–1)
TGF-b1
(pgml–1)
TSN 1 6.3 17.8 3.2 211.8 10,985.6 15.8 1.2 39.7 13.6 164.9 38.8
TSN 2 ND 76.1 5.9 162.9 11,098.0 34.8 ND 43.9 25.1 545.2 31.5
TSN 3 ND 43.8 1.8 2,821.1 10,704.9 ND 1.3 480.3 6.3 1,489.2 67.7
TSN 4 ND ND ND ND 3.0 ND ND ND ND 103.0 20.3
TSN 5 8.0 2.8 0.1 9.6 282.9 ND ND ND ND 231.5 46.7
TSN 6 8.0 0.2 ND 0.9 145.4 ND ND ND ND 94.2 11.0
TSN 7 ND 1.1 5.1 108.6 14,948.5 ND 0.5 62.9 5.6 763.6 21.9
TSN 8 ND 26.3 4.8 510.7 12,005.4 41.4 0.5 171.6 21.4 706.0 26.5
TSN 9 ND 30.2 5.3 530.4 11,517.7 ND ND 64.1 20.1 171.2 20.9
TSN 10 ND 25.8 6.2 107.8 6,815.9 14.6 0.3 53.7 8.3 398.6 44.1
TSN 11 16.8 3.1 0.7 17.8 479.0 ND 1.9 10.9 3.5 110.2 22.0
TSN 12 ND 20.2 7.6 469.3 12,037.7 10.2 1.1 49.9 6.2 117.1 28.1
Media 1 ND ND ND ND ND ND ND ND ND ND 11.0
Media 2 ND ND ND ND ND ND ND ND ND ND 10.1
Media 3 ND ND ND ND ND ND ND ND ND ND 11.1
Abbreviations: ND, not detected; SCC, squamous cell carcinoma; TGF-b, transforming growth factor-b; TNF-a, tumor necrosis factor-a; TSN, tumor
supernatant; VEGF, vascular endothelial growth factor.
Size-comparable specimens of whole-tissue SCC specimens were cultured for 24 hours, and the contents of IFN-g, IL-1b, IL-2, IL-6, IL-8, IL-12p70, TNF-a,
GM-CSF, IL-10, VEGF, and TGF-b1 in the supernatants were analyzed using an electrochemiluminescence-based method. Media 1–3 represent the media
used for the culture of SCC specimens.
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carry tumor immunosuppressive cytokines, such as VEGF,
TGF-b1, IL-10, and IL-6.
DISCUSSION
The induction of effective anticancer response depends
on innate and adaptive immunity coordinated by DCs
(Pinzon-Charry et al., 2005). However, the dysfunction of
DCs in tumor tissue has been noted in various types
of cancer. Similar findings have also been reported in
the blood-circulating DCs from cancer patients (Almand
et al., 2000, 2001; Della Bella et al., 2003). These
observations suggest that DC dysfunction may be a sys-
temic event rather than a phenomenon simply confined
to the local tumor microenvironment (Pinzon-Charry et al.,
2005; Bennaceur et al., 2008). We previously showed
that the T-cell stimulatory capacity of myeloid DCs from
human cutaneous SCC is considerably impaired (Bluth et al.,
2009). In this study, we evaluated the function of a different
DC subset, epidermal LCs, isolated from cutaneous SCC.
In sharp contrast to myeloid DCs, LCs from SCC were
more powerful stimulators of allogeneic CD4þ and CD8þ
T-cell proliferation than LCs from PTNL skin. This result
was consistent with the more mature phenotype of SCC-
derived LCs. Furthermore, LCs from SCC were superior to
those from PTNL skin in polarizing CD4þ and CD8þ T cells
to produce IFN-g, a key cytokine required for anti-
tumor immunity. Thus, contrary to cancer-associated myeloid
DCs, LCs in SCC exhibited enhanced ability to stimulate
T-cell proliferation and drive desirable type 1 T-cell
responses.
In vitro, the proliferation of both CD4þ and CD8þ T cells
driven by LCs from normal skin was augmented in the
presence of TSN. TSN was stimulatory, despite the fact that
we found it was rich in DC-suppressive cytokines. This is
consistent with the results obtained from the comparison
between SCC-derived LCs and those from PTNL skin. The
effect of TSN was specific to IFN-g induction by CD8þ
T cells, and did not lead to induction of CD8þ T cells
producing IL-4, IL-17, or IL-22. The ability of epidermal
LCs to both induce T-cell proliferation and drive IFN-g
response was enhanced even in the presence of tumor-
derived soluble immunosuppressive mediators; this implies
that T-cell proliferation and type 1 immune response based
on LC/T-cell interactions are not vulnerable to the immuno-
suppressive SCC microenvironment. This is consistent
with the report that the T-cell stimulatory ability of LCs
is not affected by melanoma cell–derived factors (Berthier-
Vergnes et al., 2001). LCs isolated from the lymph nodes
of tumor-bearing mice are also shown to be fully com-
petent in stimulating T-cell proliferation (Ishida et al., 1998).
Taken together, these findings support the concept
that epidermal LCs seem to be a unique DC subset that is
resistant to a predominantly immunosuppressive tumor
environment.
Nevertheless, patients’ immune systems fail to eradicate
SCC tumors, despite the enhanced ability of SCC-derived LCs
to induce strong type 1 immunity ex vivo. This implies that
tumor-specific immunity elicited by LCs is suboptimal in situ.
One plausible explanation for this discrepancy is the
relatively low number of LCs in the tumor nests. We and
others have observed lower numbers of LCs in the SCC
microenvironment (Galan and Ko, 2007; Bluth et al., 2009;
Takahara et al., 2009). We found fewer CD1aþ and
Langerinþ cells infiltrating SCC tumor nests and even fewer
Langerhans cells in adjacent nontumor-bearing skin
(Bluth et al., 2009). Other potential mechanisms include
defective recognition, internalization, processing, and pre-
sentation of tumor antigens by LCs, as well as a deficit
in their migration to gain access to T cells. Physical contact of
LCs with immunosuppressive cells such as regulatory T cells
and the presence of myeloid-derived suppressor cells in the
tumor microenvironment should also be taken into con-
sideration.
As isolated LCs are immunologically active, they may
have potential in LC-based SCC immunotherapy. One of the
major strategies for DC-based cancer immunotherapy is the
transfer of DCs generated from precursors under ex vivo
tumor-free conditions (Schuler et al., 2003; Steinman and
Banchereau, 2007; Banchereau et al., 2009). Most studies use
DCs induced from peripheral blood monocytes (Nestle et al.,
1998; Thurner et al., 1999; Berntsen et al., 2006; Palucka
et al., 2006). DCs derived from CD34þ HPCs, containing LC-
type DCs, have also been used for this purpose (Banchereau
et al., 2001; Di Nicola et al., 2004). We demonstrated that
the ability of LC-type DCs to expand CD4þ and CD8þ
T cells and drive IFN-g response was significantly enhanced
in the presence of SCC-derived factors; in contrast, the
activity of monocyte-derived DCs was suppressed by SCC-
derived factors. These results are consistent with previous
reports that LC-type DCs or total DCs derived from CD34þ
HPCs are superior to monocyte-derived DCs in the induction
of antigen-specific CD8þ T cells (Mortarini et al., 1997;
Ferlazzo et al., 1999; Ratzinger et al., 2004). Both SCC-
derived LCs and LC-type DCs showed the ability to stimulate
T-cell proliferation and promote desirable type 1 immune
response. As the tumor microenvironment may suppress
myeloid DC activity (Vicari et al., 2002), our results support
an idea that in vitro–generated LCs may be suitable for cancer
immunotherapy (Banchereau et al., 2001). Although the
mechanisms underlying the observed differences between the
two types of DC remain undefined, we believe our data lend
a new rationale to the use of LC-type DCs in cancer vaccine
therapy.
Another promising strategy for DC-based cancer immuno-
therapy is the targeted delivery of tumor antigens to in vivo
DCs, either by using anti-DC antibodies such as CD205 and
CD207 or by simple and direct application on barrier-
disrupted skin (Steinman and Banchereau, 2007; Flacher
et al., 2009; Romani et al., 2010; Stoitzner et al., 2010). Skin
DCs, especially LCs, are targeted in this approach because of
relatively easy access. Indeed, the pivotal role of LCs in the
protecting effect of epicutaneous immunization in tumor-
bearing mice has been shown using the LC-depletion model
(Stoitzner et al., 2008). Considering that myeloid DCs can be
systemically impaired in cancer patients, our observation that
epidermal LCs in tumor-associated environment acted
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as even more powerful antigen-presenting cells also
supports the validity of this second maneuver exploiting
in vivo LCs.
The immune microenvironment associated with cuta-
neous SCC is a highly complex milieu comprising opposing
forces driving activation of one DC type and suppression of
another. The observed contrasting effects of TSN may be
the result of the combined effect of a wide range of
soluble mediators that are both stimulatory and inhibitory.
The simultaneous upregulated gene expression of both
immunostimulatory and immunosuppressive molecules in
SCC-derived LCs might reflect this complicated tumor
microenvironment as well. Our results demonstrate that the
cancer microenvironment can affect distinct DC subtypes in
totally different ways.
One potential explanation for our findings may reside in
the CLEC2D/CD161 axis. CLEC2D is a C-type lectin that has
been linked to IFN-g induction via interaction with CD161 on
T cells (Aldemir et al., 2005). Maggi et al. (2010) showed that
CD161 is expressed by Th1, Th2, Th0, and Th17 cells and is
inducible by RORC. We found that CLEC2D was over-
expressed in LCs from SCC (3.5- to 4.8-fold, Po0.004
0.0001) based on expression of probes 220132-s, 233500_x
and 23522 (Supplementary Table S1 online). Thus, it
may be that LC expression of CLEC2D may be important in
initiating type 1 antitumor immunity. The mechanisms
governing these processes will be the focus of ongoing work
by our group.
In conclusion, we have shown the evidence that human
LCs act as powerful inducers of type 1 T-cell response in the
cancer microenvironment. Our findings provide a new
rationale to the use of LCs for DC-based cancer immunother-
apy, and thus pave the way to new cancer immunotherapy
based on LC function.
MATERIALS AND METHODS
The study was approved by the institutional review board of Weill
Cornell Medical College and the Rockefeller University. Written
informed consent was obtained before enrolling patients to
participate in this study. The study was performed in adherence
with the Declaration of Helsinki Principles.
Skin sample preparation for flow cytometry
Tumors of cutaneous SCC and site-matched PTNL skin were
obtained at surgery, and normal skin was obtained as the discarded
product of dermatologic and plastic surgery. All SCCs were primary
stage 1 SCCs from sun-exposed areas of the head and neck.
Epidermal single-cell suspensions were prepared using Dispase II
(Roche Diagnostics, Mannheim, Germany) and trypsin-ethylenedi-
amine tetraacetic acid (Invitrogen, Carlsbad, CA) as described
previously (Fujita et al., 2009).
Flow cytometry
FACS of epidermal HLA-DRþCD207þ LCs, as well as FACS
phenotyping of epidermal LCs and in vitro–generated LC-type
DCs, was performed as previously described (Fujita et al.,
2009). Antibodies used are outlined in Supplementary Table S2
online.
Generation of LC-type DCs in vitro
LC-type DCs were obtained by culturing CD34þ HPCs with GM-
CSF (100 ngml–1; R&D Systems, Minneapolis, MN), fms-like tyrosine
kinase 3 ligand (100 ngml–1; R&D Systems), and TNF-a (10 ngml–1;
R&D Systems) for 8 days as previously described (Fujita et al., 2009).
On day 8, CD1aþCD14 LC-type DCs were sorted on a FACSAria
(BD Biosciences, San Jose, CA).
Generation of monocyte-derived conventional DCs
Monocyte-derived DCs were obtained by culturing peripheral blood
mononuclear cells with 25 ngml–1 IL-4 and 100ngml–1 GM-CSF
(both from R&D Systems) for 8 days as previously described (Fujita
et al., 2009). On day 8, live and forward scatter– and side
scatter–high cells were sorted on a FACSAria for purification of DCs.
MLR assay
The MLR assay was performed as previously described (Fujita et al.,
2009). For the evaluation of cell proliferation, T cells were labeled
with CFSE using the Vybrant CFDA SE Cell Tracer Kit (Invitrogen/
Molecular Probes) as previously described (Fujita et al., 2009).
Intracellular cytokine staining
T cells stimulated with allogeneic LCs/DCs for 7 days were restimulated
for 4hours with 25mgml–1 phorbol 12-myristate 13-acetate and
2mgml–1 ionomycin in the presence of 10Mgml–1 brefeldin A (all
from Sigma Aldrich, St Louis, MO) at 37 1C. Intracellular cytokine
staining was then performed as previously described (Fujita et al.,
2009). Antibodies used are outlined in Supplementary Table S1online.
Expression of each molecule was analyzed in activated (forward
scatter– and side scatter–high cells) T cells.
Collection of TSNs
Freshly excised whole-tissue specimens of cutaneous SCC of uniform
size (B1.5 cm2) were cut into small pieces with a scalpel and
incubated at 37 1C in a six-well plate in 2ml of complete medium.
Medium was harvested after 24 hours of culture and centrifuged at
1,500 r.p.m. for 5minutes, and then supernatants were collected and
run over a 0.22-mm Millex-GP filter (Millipore, Bedford, MA) and
stored at 20 1C. The supernatants were added to the MLR culture in
a 1:4 dilution as described previously (Enk et al., 1997).
Measurement of cytokines in SCC supernatants
Levels of VEGF, TGF-b1, and proinflammatory cytokines including
IFN-g, IL-1b, IL-2, IL-6, IL-8, IL-12p70, TNF-a, GM-CSF, and IL-10 in
the SCC supernatants were measured using an electrochemilumi-
nescence-based Human VEGF Tissue Culture Assay, Human TGF-b1
Assay, or Human Pro-inflammatory 9-Plex Tissue Culture Kit (Meso
Scale Discovery, Gaithersburg, MD). Samples were analyzed in
duplicate and compared with control culture media used for culture.
Plates were read in a SECTOR Imager 2400 instrument (Meso Scale
Discovery).
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